Relative Bioavailability, Safety and Tolerability of Two Tablet Formulations of BIIL 284 BS

NCT02265666 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: BIIL 284 BS Tablet FF
DRUG: BIIL 284 BS tablet C
OTHER: standard breakfast

Sponsor

Boehringer Ingelheim